Co-Authors
This is a "connection" page, showing publications co-authored by Sunita Gulati and Jutamas Shaughnessy.
Connection Strength
1.590
-
Gulati S, Mattsson AH, Schussek S, Zheng B, DeOliveira RB, Shaughnessy J, Lewis LA, Rice PA, Comstedt P, Ram S. Preclinical efficacy of a cell division protein candidate gonococcal vaccine identified by artificial intelligence. mBio. 2023 Dec 19; 14(6):e0250023.
Score: 0.222
-
Shaughnessy J, Chabeda A, Tran Y, Zheng B, Nowak N, Steffens C, DeOliveira RB, Gulati S, Lewis LA, Maclean J, Moss JA, Wycoff KL, Ram S. An optimized Factor H-Fc fusion protein against multidrug-resistant Neisseria gonorrhoeae. Front Immunol. 2022; 13:975676.
Score: 0.204
-
Shaughnessy J, Tran Y, Zheng B, DeOliveira RB, Gulati S, Song WC, Maclean JM, Wycoff KL, Ram S. Development of Complement Factor H-Based Immunotherapeutic Molecules in Tobacco Plants Against Multidrug-Resistant Neisseria gonorrhoeae. Front Immunol. 2020; 11:583305.
Score: 0.180
-
Gulati S, Pennington MW, Czerwinski A, Carter D, Zheng B, Nowak NA, DeOliveira RB, Shaughnessy J, Reed GW, Ram S, Rice PA. Preclinical Efficacy of a Lipooligosaccharide Peptide Mimic Candidate Gonococcal Vaccine. mBio. 2019 11 05; 10(6).
Score: 0.168
-
Gulati S, Beurskens FJ, de Kreuk BJ, Roza M, Zheng B, DeOliveira RB, Shaughnessy J, Nowak NA, Taylor RP, Botto M, He X, Ingalls RR, Woodruff TM, Song WC, Schuurman J, Rice PA, Ram S. Complement alone drives efficacy of a chimeric antigonococcal monoclonal antibody. PLoS Biol. 2019 06; 17(6):e3000323.
Score: 0.164
-
Gulati S, Shaughnessy J, Ram S, Rice PA. Targeting Lipooligosaccharide (LOS) for a Gonococcal Vaccine. Front Immunol. 2019; 10:321.
Score: 0.160
-
Shaughnessy J, Lewis LA, Zheng B, Carr C, Bass I, Gulati S, DeOliveira RB, Gose S, Reed GW, Botto M, Rice PA, Ram S. Human Factor H Domains 6 and 7 Fused to IgG1 Fc Are Immunotherapeutic against Neisseria gonorrhoeae. J Immunol. 2018 11 01; 201(9):2700-2709.
Score: 0.156
-
Shaughnessy J, Gulati S, Agarwal S, Unemo M, Ohnishi M, Su XH, Monks BG, Visintin A, Madico G, Lewis LA, Golenbock DT, Reed GW, Rice PA, Ram S. A Novel Factor H-Fc Chimeric Immunotherapeutic Molecule against Neisseria gonorrhoeae. J Immunol. 2016 Feb 15; 196(4):1732-40.
Score: 0.129
-
Beernink PT, Di Carluccio C, Marchetti R, Cerofolini L, Carillo S, Cangiano A, Cowieson N, Bones J, Molinaro A, Paduano L, Fragai M, Beernink BP, Gulati S, Shaughnessy J, Rice PA, Ram S, Silipo A. Gonococcal Mimitope Vaccine Candidate Forms a Beta-Hairpin Turn and Binds Hydrophobically to a Therapeutic Monoclonal Antibody. JACS Au. 2024 Jul 22; 4(7):2617-2629.
Score: 0.058
-
Bettoni S, Shaughnessy J, Maziarz K, Ermert D, Gulati S, Zheng B, M?rgelin M, Jacobsson S, Riesbeck K, Unemo M, Ram S, Blom AM. C4BP-IgM protein as a therapeutic approach to treat Neisseria gonorrhoeae infections. JCI Insight. 2019 12 05; 4(23).
Score: 0.042
-
Ngampasutadol J, Ram S, Gulati S, Agarwal S, Li C, Visintin A, Monks B, Madico G, Rice PA. Human factor H interacts selectively with Neisseria gonorrhoeae and results in species-specific complement evasion. J Immunol. 2008 Mar 01; 180(5):3426-35.
Score: 0.037
-
Ram S, Shaughnessy J, de Oliveira RB, Lewis LA, Gulati S, Rice PA. Gonococcal lipooligosaccharide sialylation: virulence factor and target for novel immunotherapeutics. Pathog Dis. 2017 06 01; 75(4).
Score: 0.036
-
Ram S, Shaughnessy J, DeOliveira RB, Lewis LA, Gulati S, Rice PA. Utilizing complement evasion strategies to design complement-based antibacterial immunotherapeutics: Lessons from the pathogenic Neisseriae. Immunobiology. 2016 10; 221(10):1110-23.
Score: 0.033